Gilead Sciences (GILD) Stock Price, Quote, News & History | Benzinga

Gilead Sciences Inc (GILD) Stock Price, Quote, News & History

GILDNASDAQ

Trade with Public

Trade with Public

$135.64

-0.13-0.1%

Last update: Aug 12, 2:27 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

$133.99

Close

-

Volume / Avg.

2.82M / 7.68M

Day Range

$133.29 - $137.12

52 Wk Range

108.46 - 157.29

Market Cap

$168.19B

P/E Ratio

-

Dividend Yield

2.42%

Exchange

NASDAQ

RSI

58

Short Interest

1.97%

Days to Cover

3.86

Recent Gilead Sciences, Inc News

KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’

Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb.

Avi Kapoor

Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.

Tanya Rawat

SpaceX Could Swing $204 Billion After Earnings

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.

Kaustubh Bagalkote

Eli Lilly Could Swing Over $76 Billion In Value After Earnings

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings reports.

Kaustubh Bagalkote

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

13.55B

Investing Cash Flow (TTM)

-10.84B

Financing Cash Flow (TTM)

-4.65B

Free Cash Flow (TTM)

12.94B

Capital Expenditure (TTM)

-609.00M

Net Change in Cash (TTM)

-1.94B

Analyst Trends and Forecast

2

Apr

2

May

1

Jun

5

2

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$191.42B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.56

PB Ratio (TTM)

14.23

Earnings Yield % (TTM)

-1.95%

Earnings Yield % (FWD)

-0.45%

EV / EBITDA (TTM)

106.17

Price / EBITDA (TTM)

93.98

Price / Free Cash Flow (TTM)

13.09

Book Value / Share

$9.54

Company Debt

Total Debt

$26.25B

LT Debt

$23.83B

LT Debt Issuance (TTM)

$4.09B

LT Debt Repayment (TTM)

-$2.80B

Total Cash

$3.18B

Debt to Equity

2.22

Issuance of Debt (TTM)

$1.29B

Repayment of Debt (TTM)

-$2.80B

Key Statistics

Open

$133.99

Close

-

Volume / Avg.

2.82M / 7.68M

Day Range

$133.29 - $137.12

52 Wk Range

108.46 - 157.29

Market Cap

$168.19B

P/E Ratio

-

Dividend Yield

2.42%

Exchange

NASDAQ

RSI

58

Short Interest

1.97%

Days to Cover

3.86

About

Sector

Health Care

Industry

Biotechnology

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Gilead Sciences (GILD) stock?

A

You can purchase shares of Gilead Sciences (NASDAQ:GILD) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Gilead Sciences (GILD) competitors?

A

Other companies in Gilead Sciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and argenx SE (NASDAQ:ARGX).

Q

What is the forecast, or price target, for Gilead Sciences (GILD) stock?

A

Gilead Sciences has a consensus price target of $135.30.

Q

What is the current price for Gilead Sciences (GILD)?

A

The stock price for Gilead Sciences (NASDAQ: GILD) is $135.64 last updated August 12, 2026 at 2:27 PM EDT.

Q

Does Gilead Sciences (GILD) pay a dividend?

A

There are no upcoming dividends for Gilead Sciences.

Q

When is Gilead Sciences (NASDAQ:GILD) reporting earnings?

A

Gilead Sciences does not have any upcoming earnings scheduled.

Q

Is Gilead Sciences (GILD) going to split?

A

There is no upcoming split for Gilead Sciences.

Q

What sector and industry does Gilead Sciences (GILD) operate in?

A

Gilead Sciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.